Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Blast clearance dynamics and time to response across IDH1- and IDH2-mutated AML

View Full Paper
Ask AI
Bookmark
Share

Authors

MNMohamad Sheikh NajeebMayo ClinicPGPatricia T. GreippBrigham and Women's Hospital
Mark R. Litzow
Mark R. LitzowNorthwestern University

Discussion

Loading...

Member takes

Overview

Analysis demonstrates varied response dynamics in blast clearance for IDH1 and IDH2 mutants, indicating distinct treatment implications.

Key Points

  • This research aims to evaluate response dynamics in AML patients with IDH1 and IDH2 mutations to intensive chemotherapy.
  • Chart review of AML patients diagnosed at Mayo Clinic from 2016 to 2023
  • Evaluation of bone marrow blast percentages at mid-cycle and end of cycle
  • Statistical analysis using GraphPad Prism 10.0.0
  • Among IDH2 mutants, R140 showed lower median mid-cycle blast percentages than R172
  • Higher proportion of IDH2 R140 patients achieved blast clearance compared to R172
  • No significant differences in overall survival between IDH1 and IDH2 mutated patients

Cite This Study

Najeeb et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d555https://doi.org/10.1182/blood-2025-7045
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1IDH2 R172 mutation is associated with improved survival in IDH-mutated AML/MDS patients undergoing allogeneic stem cell transplantation: A geth-TC multicenter study2025
  2. 2IDH mutant MDS: Proposal for disease subset recognition based on molecular and clinical features, and the availability of targeted therapies2025
  3. 3Isocitrate Dehydrogenase (IDH) 1 and 2 Mutations Predicts Better Outcome in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation: a study of the ALWP of the EBMT2024
  4. 4Mutations in IDH1 and IDH2 portend a poor prognosis in adult patients with acute lymphoblastic leukemia2025
  5. 5Treatment responses and survival of newly diagnosed older or unfit patients (pts) with IDH1/2-mutated Acute Myeloid Leukemia (AML): An analysis of the MARROW consortium2025